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THE CYCLE OF C. DIFFICILE 
Britton R, Young V.  Gastroenterology 2014;146. 
THE INCREASING PROBLEM OF C. DIFF INFECTION 
Lessa FC, et al. CID 2012:55 
Redelings MD, et al. EID, 2007 
 
C diff- related mortality rates per 
million population, US, 1999–2004 
HIGH RATES OF RECURRENT C. DIFF INFECTION  
• 20% after initial treatment 
• 40% after first recurrence 
• 60% after 2 or more recurrences 
• High cost of “vancomycin dependent” treatment 
– 125 mg (1 box, 20 ea): $673.99 
– Cost of taper: $2864  
McFarland LV. J Med Micro 2005 
McFarland LV. J Clin Gastro 2002 
Kelly C. JAMA 2009 
Walgreens.com 
 
DECREASED DIVERSITY OF COLONIC MICROFLORA 
IN C. DIFF INFECTION 
 
Chang, et al. JID 2008 
FECAL MICROBIOTA TRANSPLANTATION 
• Administration of feces from a healthy 
individual to promote colonization with 
beneficial gut flora  
• aka…Fecal bacteriotherapy, Stool 
transplant, Fecal flora reconstitution 
Borody TJ. J Clin Gastro 2004 
RANDOMIZED TRIAL SUPPORTING FMT SUSPENDED 
Van Nood E, et al. NEJM 2013. 
Microbiota 
Diversity  
INDICATIONS FOR FMT 
1. Recurrent or relapsing CDI 
– At least three episodes of mild-to-moderate CDI and failure of a 
6-8 week taper with vancomycin with or without an alternative 
antibiotic (e.g., rifaximin, fidaxomicin, nitazoxanide) 
– At least two episodes of severe CDI resulting in hospitalization 
and associated with significant morbidity 
 
2. Moderate CDI not responding to standard therapy 
(vancomycin) for at least a week 
 
3. Severe (and perhaps fulminant C. difficile colitis) 
with no response to standard therapy after 48 hours 
Bakken et al. Clin Gastro Hepatol 2011 
SUSPECTED MECHANISM – LIKE RESODDING 
The Good The Bad 
The Reconstituted 
Courtesy of Dr. Colleen Kelly 
MONITORING FOR SAFETY ISSUES 
• No adverse events or infectious 
complications yet reported 
• Risk of infection 
• Theoretical risks: allergic, autoimmune, 
IBD, neurologic, obesity, cancer 
SHOULD FDA REGULATE FMT? 
• FDA has declared jurisdiction 
• Does not wish to “interfere with patient care” 
• Consideration of seeking IND approval 
• Allowing FMT with standard practices and informed 
consent for C. diff infection 
• Outcomes and Data Collection for Fecal Microbiota 
Transplantation for the Treatment of Recurrent 
Clostridium difficile 
• IRB-approved protocol for colonoscopy administration 
• Not indicated or acceptable therapy for IBD presently 
• Contacts  
– anne.foley@umassmemorial.org 
– randall.pellish@umassmemorial.org 
 
FMT AT UMASSMEMORIAL 
FOR RECURRENT C. DIFF INFECTION 
• Retrospective case series of FMT in IC patients 
– Overall cure rate was 89% 
– No infections definitively related to FMT 
• UMass proposal in discussion 
– Bank stool of solid organ transplant patients prior to 
transplant 
– Autologous fecal transplant for C. diff infection post 
transplant 
FMT FOR IMMUNOCOMPROMISED (IC) PATIENTS? 
Kelly C, submitted manuscript 
• Intestinal microbiota in IBD patients less diverse 
– Studies reporting 25% fewer microbial genes 
• Microbiota variations in IBD 
– Reduced Firmicutes and Bacteroides 
– Increased Actinobacteria and Proteobacteria 
– Decreased Feacalibacterium prausnitzii in Crohn’s 
– Differences a cause or consequence of IBD?? 
RATIONALE FOR FMT  
IN INFLAMMATORY BOWEL DISEASE 
Gastroenterology 2013;145:946–953 
• Openbiome.org 
• Frozen stool preparations 
• Defined, full-spectrum microbiota 
treatments 
• FMT in IBD…not there yet 
FUTURE DIRECTIONS  
